B2BinPay v20 Increases Functionality with TRX Staking and Broader Blockchain Support
6.6.2024 11:31:00 EEST | Business Wire | Press release
The industry-leading blockchain platform, B2BinPay, has improved even further. The most recent version offers clients more flexibility and efficiency by expanding blockchain functionality and introducing TRX staking. Let's review how these new features improve B2BinPay's user experience.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240606092849/en/
B2BinPay version 20 arrives with TRX staking feature and expanded blockchain support (Graphic: Business Wire)
TRX Staking – Earn While You Transact!
The launch of TRX Staking, based on the advanced Stake 2.0 mechanism developed by the TRON community, is a crucial highlight of B2BinPay v20. With its increased flexibility, simplified user interface, and improved resource delegation and utilisation efficiency, this new approach surpasses the previous Stake 1.0.
TRX staking empowers B2BinPay clients to stake any amount of TRX and earn a passive annual yield of 3-5% (subject to network conditions). But this is not all. By staking TRX, users can significantly reduce transaction fees on the TRON network. Staked TRX is converted into bandwidth and energy, two necessary resources, to achieve this.
Smart contracts run on energy, and transaction processing capability is provided by bandwidth. By staking TRX and acquiring these resources, companies and individuals can increase transaction efficiency and save operating costs, providing them a distinct competitive advantage.
Getting started with TRX Staking on B2BinPay is straightforward:
➔ Begin by converting your TRX into either Bandwidth or Energy based on the specific processing needs of your chosen asset type.
➔ After that, delegate your votes converted from Bandwidth or Energy to SR.
New Blockchains Supported
Building on the previous integration of Polygon and Avalanche, the addition of Optimism, Arbitrum, and Base—all of which provide native support for stablecoins—significantly broadens B2BinPay v20's support for blockchain technology.
Optimism
Optimism is a Layer 2 solution that scales the Ethereum leading network by batching transactions. It collects transaction data from the Ethereum blockchain, processes it in batches, and sends it back to the Ethereum mainnet for validation. Since its launch in 2021, Optimism has reduced fees by ten times compared to Ethereum's base level. Users have saved over $1 billion in gas payments, making it one of the most cost-effective blockchains.
Arbitrum
Arbitrum is an Ethereum scaling solution that increases transaction volumes while lowering costs. It shares Ethereum's tooling, enabling developers to deploy DApps on Arbitrum quickly and securely. This compatibility extends to stablecoins, offering users more choices.
Base
Base, developed by Coinbase, optimises Optimism’s OP Stack for enhanced EVM compatibility. This open-source rollup supports stablecoins and makes code deployment easier on Ethereum and compatible blockchains.
Why Does Expanded Blockchain Support Matter for Clients?
By incorporating additional blockchains, B2BinPay expands the range of transaction options, aligning with your business requirements using suitable technology. Specifically, B2BinPay now supports:
USDT on 7 networks:Ethereum, Binance Smart Chain, Tron, Avalanche, Polygon, Optimism, and Arbitrum.
USDC on 8 networks: Ethereum, Binance Smart Chain, Tron, Avalanche, Polygon, Optimism, Arbitrum, and Base.
Bridged USDC on 4 networks: Avalanche, Polygon, Optimism, and Arbitrum.
Here are other use cases of how the blockchain expansion can benefit you.
Streamlining Withdrawals for End-Users
Suppose your end-user needs to withdraw funds in a currency that's not immediately available. In that case, B2BinPay allows for swift asset conversion to meet currency requirements and handle associated transaction fees, ensuring the timely fulfilment of withdrawal requests.
Reducing Blockchain Transaction Fees
If you aim to lower the cost of USDT transactions, B2BinPay offers an effective solution by allowing you to aggregate USDT from various blockchains, such as Ethereum or Optimism, into a single swap wallet.
Ensuring Liquidity for Trading Platforms
Suppose you have significant cryptocurrency funds and urgent requirements like stopouts on trading platforms. In that case, you can rely on B2BinPay's extensive blockchain support to quickly convert assets into the required currency for deposit. This feature assists you in maintaining liquidity and enables quick responsiveness to market demands.
Final Remarks
According to the official statements, Algorand and Solana will be introduced in the upcoming release. With this expansion, there will be 10 blockchains that enable stablecoin transactions, including those already used: Ethereum, Tron, Binance Smart Chain, Avalanche, Polygon, Optimism, Arbitrum, and Base.
Connect with B2BinPay and unlock your business potential with advanced blockchain payment processing solutions!
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240606092849/en/
Contact information
sales@b2binpay.com
+357 250-308-82
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 11:00:00 EEST | Press release
OM Pharma will reveal preliminary results from the REACH study at the European Academy of Allergy and Clinical Immunology (EAACI) Congress. REACH is the first and largest multi-country real-world evidence (RWE) study to date evaluating the impact of Broncho-Vaxom® in patients with recurrent respiratory tract infections (RTIs).1,2 The findings offer critical new clinical evidence of the therapy's effectiveness in everyday clinical practice. In a real-world cohort of 15,794 paediatric (aged >1 year), adolescent, adult and elderly patients in China, Italy, and Belgium, Broncho-Vaxom® was associated with reductions in RTI recurrence and healthcare utilisation at 12 and 24 months after treatment initiation, compared with the 12 months prior to starting the therapy.1 “The REACH real-world evidence study shows that Broncho-Vaxom® can significantly reduce infections requiring medical visits across age groups and co-morbidities,” said Anna Thomas, Chief Scientific Officer at OM Pharma. “Recurre
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 18:15:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced updated clinical data from two Phase 1 studies evaluating the safety, tolerability and efficacy of INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody, in patients with mutCALR-expressing myeloproliferative neoplasms (MPNs). INCA033989 demonstrated rapid, clinically meaningful responses and consistent molecular activity across both myelofibrosis (MF) and essential thrombocythemia (ET), with convergent evidence supporting the potential for disease modification. These findings are being presented in oral and poster presentations at the European Hematology Association (EHA) 2026 Congress in Stockholm, Sweden (Session: Myeloproliferative neoplasms – Clinical, Presentation numbers: S216, PS1983, PF884). “The data presented at EHA 2026 demonstrate clinically meaningful and consistent responses with INCA033989 across both myelofibrosis and essential thrombocythemia,” said Pablo J. Cagnoni, M.D., President of Incyte and G
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi ® /Minjuvi ® ) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 13:00:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, and lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) versus R-CHOP, the current standard of care, as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). Eligible patients had an International Prognostic Index (IPI) score of 3-5, or, for patients ≤60 years of age, an age-adjusted IPI (aaIPI) of 2-3. These data are being highlighted in a prestigious Plenary Abstracts Session at the European Hematology Association (EHA) 2026 Congress, being held June 11 - 14, 2026, in Stockholm, Sweden (Abstract # S101. Plenary Abstract Session. June 13, 6:00 - 7:30 a.m. ET [12:00-1:30 p.m. CEST]). frontMIND results were als
Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202613.6.2026 00:31:00 EEST | Press release
Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til
IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 19:36:00 EEST | Press release
IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, strategy, and business transformation. She most recently served as Global Head of Deloitte Digital and previously held senior global leadership roles,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom